New cancer drug PLT012 enters human testing for advanced tumors
NCT ID NCT07337525
First seen Jan 24, 2026 · Last updated May 01, 2026 · Updated 12 times
Summary
This early-phase study tests the safety and best dose of a new drug called PLT012 in adults with advanced solid tumors that have not responded to other treatments. About 36 participants will receive the drug by IV every three weeks. The study will monitor side effects, drug levels in the blood, and any tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Dallas
RECRUITINGDallas, Texas, 75039, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Houston
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.